Cargando…

645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II

BACKGROUND: Commercially available enzyme immunoassays (EIAs) for detection of norovirus antigen have poor sensitivity and are limited to use in investigations of a gastroenteritis outbreak. Hence, there remains a need for a standalone high-sensitivity assay that enables rapid and accurate detection...

Descripción completa

Detalles Bibliográficos
Autores principales: Dave, Gipshu, Katzenbach, Phoebe, Sandlund, Johanna, Estis, Joel, Mukherjee, Ali, Nolan, Niamh, Almazan, Anna, Hadass, Orr, Noland, Brian, Bishop, Jeffrey J, Banaei, Niaz, Riner, Diana K, Todd, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811303/
http://dx.doi.org/10.1093/ofid/ofz360.713
_version_ 1783462450482380800
author Dave, Gipshu
Katzenbach, Phoebe
Sandlund, Johanna
Estis, Joel
Mukherjee, Ali
Nolan, Niamh
Almazan, Anna
Hadass, Orr
Noland, Brian
Bishop, Jeffrey J
Banaei, Niaz
Riner, Diana K
Todd, John
author_facet Dave, Gipshu
Katzenbach, Phoebe
Sandlund, Johanna
Estis, Joel
Mukherjee, Ali
Nolan, Niamh
Almazan, Anna
Hadass, Orr
Noland, Brian
Bishop, Jeffrey J
Banaei, Niaz
Riner, Diana K
Todd, John
author_sort Dave, Gipshu
collection PubMed
description BACKGROUND: Commercially available enzyme immunoassays (EIAs) for detection of norovirus antigen have poor sensitivity and are limited to use in investigations of a gastroenteritis outbreak. Hence, there remains a need for a standalone high-sensitivity assay that enables rapid and accurate detection of norovirus antigen. METHODS: The Singulex Clarity norovirus assay is currently in development for use on the Singulex Clarity(®) system (Singulex Inc., Alameda, CA, USA), a fully-automated platform powered by Single Molecule Counting technology (registered with the FDA and CE marked). The assay uses paramagnetic microparticles bound to capture antibody and a fluorescently labeled reporter antibody to detect virion capsid protein of norovirus genogroups I (GI) and II (GII) in the stool. For the development of Clarity Norovirus assay, diagnostic performance of 4 antibody pairs (as Capture and Detection reagent) were evaluated by testing 137 stool samples from patients with suspected norovirus infection. Samples were sourced from three providers: (1) 90 genotyped samples of which 75 were positive (19 different genotypes) and 15 were negative by the CDC assay, (2) 3 samples positive and 5 samples negative by the BioFire(®) FilmArray(®) Gastrointestinal Panel, and (3) 39 samples negative by a lab-developed test using Cepheid reagents (SmartCycler®). RESULTS: From all the antibody pairs tested, one of the pairs had best performance with the area under the receiver operating characteristic (AuROC) curve demonstrating a C-Statistic of 0.959 (95% CI 0.921–0.997), compared with AuROC C-statistic of 0.943 (95% CI 0.896–0.990), 0.871 (95% CI 0.807–0.936), and 0.914 (95% CI 0.863–0.964) for the three other pairs. The Clarity assay detected all 19 different genotypes tested (figures). CONCLUSION: The ultrasensitive and rapid Clarity norovirus assay (in development) for detection of GI and GII demonstrated excellent performance with one of the antibody pairs tested and detected all 19 tested genotypes. The Clarity assay may offer a standalone solution for norovirus diagnostics. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811303
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68113032019-10-29 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II Dave, Gipshu Katzenbach, Phoebe Sandlund, Johanna Estis, Joel Mukherjee, Ali Nolan, Niamh Almazan, Anna Hadass, Orr Noland, Brian Bishop, Jeffrey J Banaei, Niaz Riner, Diana K Todd, John Open Forum Infect Dis Abstracts BACKGROUND: Commercially available enzyme immunoassays (EIAs) for detection of norovirus antigen have poor sensitivity and are limited to use in investigations of a gastroenteritis outbreak. Hence, there remains a need for a standalone high-sensitivity assay that enables rapid and accurate detection of norovirus antigen. METHODS: The Singulex Clarity norovirus assay is currently in development for use on the Singulex Clarity(®) system (Singulex Inc., Alameda, CA, USA), a fully-automated platform powered by Single Molecule Counting technology (registered with the FDA and CE marked). The assay uses paramagnetic microparticles bound to capture antibody and a fluorescently labeled reporter antibody to detect virion capsid protein of norovirus genogroups I (GI) and II (GII) in the stool. For the development of Clarity Norovirus assay, diagnostic performance of 4 antibody pairs (as Capture and Detection reagent) were evaluated by testing 137 stool samples from patients with suspected norovirus infection. Samples were sourced from three providers: (1) 90 genotyped samples of which 75 were positive (19 different genotypes) and 15 were negative by the CDC assay, (2) 3 samples positive and 5 samples negative by the BioFire(®) FilmArray(®) Gastrointestinal Panel, and (3) 39 samples negative by a lab-developed test using Cepheid reagents (SmartCycler®). RESULTS: From all the antibody pairs tested, one of the pairs had best performance with the area under the receiver operating characteristic (AuROC) curve demonstrating a C-Statistic of 0.959 (95% CI 0.921–0.997), compared with AuROC C-statistic of 0.943 (95% CI 0.896–0.990), 0.871 (95% CI 0.807–0.936), and 0.914 (95% CI 0.863–0.964) for the three other pairs. The Clarity assay detected all 19 different genotypes tested (figures). CONCLUSION: The ultrasensitive and rapid Clarity norovirus assay (in development) for detection of GI and GII demonstrated excellent performance with one of the antibody pairs tested and detected all 19 tested genotypes. The Clarity assay may offer a standalone solution for norovirus diagnostics. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811303/ http://dx.doi.org/10.1093/ofid/ofz360.713 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Dave, Gipshu
Katzenbach, Phoebe
Sandlund, Johanna
Estis, Joel
Mukherjee, Ali
Nolan, Niamh
Almazan, Anna
Hadass, Orr
Noland, Brian
Bishop, Jeffrey J
Banaei, Niaz
Riner, Diana K
Todd, John
645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II
title 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II
title_full 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II
title_fullStr 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II
title_full_unstemmed 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II
title_short 645. Singulex Clarity Norovirus Assay (In Development) Provides Ultrasensitive Detection of Norovirus Genogroups I and II
title_sort 645. singulex clarity norovirus assay (in development) provides ultrasensitive detection of norovirus genogroups i and ii
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811303/
http://dx.doi.org/10.1093/ofid/ofz360.713
work_keys_str_mv AT davegipshu 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT katzenbachphoebe 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT sandlundjohanna 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT estisjoel 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT mukherjeeali 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT nolanniamh 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT almazananna 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT hadassorr 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT nolandbrian 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT bishopjeffreyj 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT banaeiniaz 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT rinerdianak 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii
AT toddjohn 645singulexclaritynorovirusassayindevelopmentprovidesultrasensitivedetectionofnorovirusgenogroupsiandii